Volume | 0.00 |
|
|||||
News | - |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Acerus Pharmaceuticals Corporation (QB) | ASPCF | OTCMarkets | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.21988 | 0.21988 |
Trades | Volume | Avg Volume |
---|---|---|
0 | 0.00 | - |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 0.21988 | USD |
Acerus Pharmaceuticals Corporation (QB) Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 1.69M | 7.71M | 662.94k | - | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Acerus Pharmaceuticals (QB) News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ASPCF Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
Acerus Pharmaceuticals (QB) Description
Acerus is a Canadian pharmaceutical company focused on the development, manufacture, marketing and distribution of innovative, branded products that improve the patient experience. Founded in 2008, Acerus has quickly grown into a fully integrated company with expertise in all stages of the pharmaceutical product lifecycle, and focus in the therapeutic areas of Men's Health (Urology) and Women's Health (Hormone Replacement Therapy). Acerus has global rights to NATESTO, a product utilizing our licensed nasal gel technology, is the first and only testosterone nasal gel approved in Canada, and the United States for replacement therapy in adult males diagnosed with hypogonadism. Acerus operates from a Mississauga-based office, and is listed on the Toronto Stock Exchange (TSX:ASP) |